CD8A and neoplasm: Preliminary data published from the first four dose levels of the monotherapy dose escalation arm - 16 patients treated with 1-12 mg IV Q2W - show a half-life of 1.9-5.8 days for WTX-124 and evidence of CD8+ T cell and NK cell expansion and activation in the tumor.